![Kenneth Cundy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kenneth Cundy
Directeur Technique/Scientifique/R&D chez
ANEBULO PHARMACEUTICALS, INC.
Fortune : - $ au 31/07/2026
Profil
Kenneth C.
Cundy currently works at Anebulo Pharmaceuticals, Inc., as Chief Scientific Officer from 2022.
Dr. Cundy also formerly worked at Gilead Sciences, Inc., as Senior Director-Biopharmaceutics from 1992 to 2000, CohBar, Inc., as Chief Scientific Officer from 2014 to 2022, and XenoPort, Inc., as Chief Scientific Officer from 2012 to 2014.
Dr. Cundy received his undergraduate degree from The University of Manchester and doctorate degree from the University of Kentucky.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/09/2025 | 0 ( -.--% ) | - $ | 31/07/2026 |
Postes actifs de Kenneth Cundy
| Sociétés | Poste | Début |
|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 20/05/2022 |
Anciens postes connus de Kenneth Cundy
| Sociétés | Poste | Fin |
|---|---|---|
| COHBAR | Directeur Technique/Scientifique/R&D | 31/03/2022 |
| XENOPORT, INC. | Corporate Officer/Principal | 01/11/2014 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2000 |
Formation de Kenneth Cundy
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
53
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
CohBar, Inc.
 CohBar, Inc. BiotechnologyHealth Technology Develops biotechnology products that intends to treat age-related diseases through the discovery of novel mitochondrial-derived peptides | Health Technology |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing of pharmaceutical products for the potential treatment of neurological disorders | Health Technology |
University of Kentucky
 University of Kentucky Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anebulo Pharmaceuticals, Inc.
 Anebulo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
